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Ulmus wallichiana Planchon (Family: Ulmaceae), a traditional medicinal plant, was
used in fracture healing in the folk tradition of Uttarakhand, Himalaya, India.
The present study investigated the cardioprotective effect of ethanolic extract (EE)
and butanolic fraction (BF) of U. wallichiana in isoprenaline (ISO) induced cardiac
hypertrophy in Wistar rats. Cardiac hypertrophy was induced by ISO (5 mg/kg/day,
subcutaneously) in rats. Treatment was performed by oral administration of EE and
BF of U. wallichiana (500 and 50 mg/kg/day). The blood pressure (BP) and heart rate
(HR) were measured by non-invasive blood pressure measurement technique. Plasma
renin, Ang II, NO, and cGMP level were estimated using an ELISA kit. Angiotensin
converting enzyme activity was estimated. BP and HR were significantly increased
in ISO group (130.33 ± 1.67 mmHg vs. 111.78 ± 1.62 mmHg, p < 0.001 and
450.51± 4.90 beats/min vs. 347.82± 6.91 beats/min, respectively, p< 0.001). The BP
and HR were significantly reduced (EE: 117.53± 2.27 mmHg vs. 130.33± 1.67 mmHg,
p < 0.001, BF: 119.74 ± 3.32 mmHg vs. 130.33 ± 1.67 mmHg, p < 0.001);
HR: (EE: 390.22 ± 8.24 beats/min vs. 450.51 ± 4.90 beats/min, p < 0.001, BF:
345.38 ± 6.79 beats/min vs. 450.51 ± 4.90 beats/min, p < 0.001) after the treatment
of EE and BF of U. wallichiana, respectively. Plasma renin, Ang II, ACE activity was
decreased and NO, cGMP level were increased. The EE and BF of U. wallichiana
down regulated the expression of ANP, BNP, TNF-α, IL-6, MMP9, β1-AR, TGFβ1
and up regulated NOS3, ACE2 and Mas expression level, respectively. Thus, this
study demonstrated that U. wallichiana has cardioprotective effect against ISO induced
cardiac hypertrophy.
Keywords: Ulmus wallichiana, ethnopharmacology, cardiac hypertrophy, cardiovascular disease, isoprenaline,
blood pressure, heart rate
Abbreviations: BF, butanolic fraction; BNP, brain natriuretic peptide; BP, blood pressure; cGMP, cyclic guanosine
monophosphate; DBP, diastolic blood pressure; DCFDA, 2′,7′-Dichlorodihydrofluorescein diacetate; DCF, 2′,7′-
Dichlorofluorescein; EE, ethanolic extract; FAP, N-[3-(2-furyl) acryloyl]-L-phenylalanine; GG, glycylglycine; HF, heart
failure; HR, heart rate; IBP, invasive blood pressure; IL-6, Interleukin 6; ISO, isoprenaline; MAP, mean arterial pressure;
NIBP, non-invasive blood pressure; NO, total nitrate/nitrite; qPCR, quantitative polymerase chain reaction; RAAS, Renin-
angiotensin-aldosterone system; ROS, reactive oxygen species; SBP, systolic blood pressure; TNF-α, tumor necrosis factor
alpha.
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INTRODUCTION
Cardiac hypertrophy is the abnormal growth, or thickening, of
the heart muscle, often due to chronic hypertension that leads
to HF. While in left ventricular hypertrophy, the myocardial
oxygen consumption is increased which results in decreased
coronary blood flow reserve which results in angina pectoris,
myocardial infarction, and sudden death (Levy et al., 1990). It
is estimated that nearly 23 million people are affected by HF
worldwide (McMurray et al., 1998). In India, the prevalence of
HF is around 4.6 million with an annual occurrence of nearly 1.8
million (Huffman and Prabhakaran, 2010). Cardiac hypertrophy
is a physiological adaptation which causes increased workload on
the myocardium. Hypertrophic growth is due to many types of
heart disease, including ischaemic heart disease, hypertension,
heart failure, cardiac hypertrophy, and valvular disease (Frey
et al., 2004).
Many bioactive compounds have been discovered from
plants which have flavonoids, natural phenolic compounds, and
phytoestrogens are strong antioxidant (Horáková, 2011; Yan
et al., 2013). Fruits and vegetables which are enriched with higher
content of flavonoid prevents the development of cardiovascular
disease (Horáková, 2011). Cardiac hypertrophy is inhibited by
different antioxidants caused by ROS (Tsujimoto et al., 2005;
Sheng, 2007). Quercetin (a polyphenolic flavonoid); and its
analogs and its major metabolite modulate NO/cGMP-dependent
vasorelaxation and regulate BP (Suri et al., 2010). Flavonoids
such as Quercetin (Jalili et al., 2006; Han et al., 2009; Yan et al.,
2013); Pentamethylquercetin (He et al., 2012); Hesperetin (Deng
et al., 2013); Curcumin (Li et al., 2008); Epigallocatechin-3 gallate
(EGCG) (Hao et al., 2007); Myricetin (Tiwari et al., 2009) possess
cardioprotective effect.
Ulmus wallichiana Planchon (Family: Ulmaceae), a traditional
Indian medicinal plant used as astringent, demulcent, emollient,
expectorant and diuretic (Khare, 2008). It contains quercetin
analog flavonoids (2S,3S)-(+)-3′,4′,5,7-tetrahydroxydihydro-
flavonol-6-C-β-D-glucopyranoside (K058); 6-Glucopyranosyl-
3,3′,4′,5,7-pentahydroxyflavone (K012); 6-Glucopyranosyl-
4′,5,7-trihydroxyflavanone (K068), and (2S,3S)-(+)-4′,5,7-
trihydroxydihydroflavonol-6-C-β-D-glucopyranoside (K100)
of known chemical structures (Supplementary Figure 1) and
composition (Supplementary Table 1) (Rawat et al., 2009; Sharan
et al., 2010). The characterization of compounds present in
EE and BF of U. wallichiana namely K012, K058, K068, and
K100 was reported by Maurya et al. (2014). These flavonoids are
potent for anabolic effect on osteoporotic bone (Sharan et al.,
2011), increases bone mass density, bone strength, and bone
formation rate which enhances osteoblast differentiation and
achieves peak bone in growing rats and has osteoprotective effect
on ovariectomized rats (Sharan et al., 2010). It also lowers blood
glucose level in diabetic rats (Rawat et al., 2011). The EE and BF
of U. wallichiana contains quercetin analog flavonoids (Sharan
et al., 2010).
Ulmus wallichiana is used traditionally as diuretic (Khare,
2008). A related species U. rhynchophylla, native to China,
known as Gou Teng in Chinese medicine, is used for eclampsia,
headache, dizziness, convulsions, high fever, and hypertension
(WHO). U. macrocarpa has antihypertensive and vasorelaxant
activity (Oh et al., 2008). Therefore due to diuretic property of
U. wallichiana it is used in hypertension as it contains quercetin
(a polyphenolic flavonoid) and its major metabolites modulate
NO/cGMP dependent vasorelaxation and regulates BP (Suri
et al., 2010). Due to prolong increase in BP (hypertension) there is
direct haemodynamic stress, leading to hypertrophy (Mehta et al.,
2014). Therefore, we have explored the effect of EE and BF of
U. wallichiana in cardiac hypertrophy.
The effective dose of EE ranges from 500 to 750 mg/kg and
that of BF ranges from 25 to100 mg/kg as reported in patent by
Maurya et al. (2014) (co-author of this article). We have selected
the above dose of EE (500 mg/kg) as it showed optimal decrease
in BP. As this dose is high enough to be translated from rat to
human, BF was isolated and used with effective dose of 50 mg/kg.
BF enriched with high content of quercetin analog flavonoids
compared to EE (Sharan et al., 2010). Therefore the effective dose
of EE is 500 mg/kg and that of BF is 50 mg/kg (Maurya et al.,
2014).
The anti-hypertrophic activity of U. wallichiana was remained
unexplored in cardiac hypertrophy model. In our lab, we
have explored the antihypertensive activity of EE and BF of
U. wallichiana (Syed et al., 2016). Therefore, in the present work,
we have investigated the anti-hypertrophic activity of EE and BF
of U. wallichiana in ISO induced cardiac hypertrophy.
MATERIALS AND METHODS
Chemicals and Reagents
Isoprenaline hydrochloride, Olive oil, Gum Acacia, N-[3-(2-
Furyl) acryloyl]-L-phenylalanyl-glycyl-glycine (FAPGG), 2′,7′-
Dichlorofluorescein diacetate and TRIzol reagent were procured
from Sigma–Aldrich Chemical Co., St. Louis, MO, USA. Sodium
Chloride was procured from Merck Specialities Private Limited,
Mumbai, India. Tris (Hydroxymethyl) Aminomethane was
procured from SRL Pvt. Ltd., Mumbai, India. High capacity
RNA to cDNA Reverse Transcriptase kit was procured from
Applied Biosystems, USA. 2X SYBR green Premix Ex Taq (Takara
Bio, Japan), List of rat primers for Real-Time (RT) qPCR
(Eurofins Scientific, Luxembourg) as shown in Table 1, Renin
TABLE 1 | Primers of cardiac hypertrophy related genes for RT qPCR.
Gene Forward primer Reverse primer
rANP GAGGAGAAGATGCCGGTAG CTAGAGAGGGAGCTAAGTG
rBNP TGATTCTGCTCCTGCTTTTC GTGGATTGTTCTGGAGACTG
rTNF-α CCCAGACCCTCACACTCAGAT TTGTCCCTTGAAGAGAACCTG
rIL-6 CCCTTCAGGAACAGCTATGAA ACAACATCAGTCCCAAGAAGG
rNOS3 AAAGGAAGTGCAGCAAAAGG CCCATGAGTGAGGCAGAGAT
rTGFβ1 CCTGGAAAGGGCTCAACAC CAGTTCTTCTCTGTGGAGCTGA
rACE2 TCAAGGGAAAAGAACCAGACA GGTTTCAAATCACTCACCCATAC
rAdrb1 AGAGCAGAAGGCGCTCAAG AGCCAGCAGAGCGTGAAC
rMas1 ACGTCCCCAGACCAGTCAT TGAGGAGTTCTTGTGCTGGA
rMMP9 CCTCTGCATGAAGACGACATAA GGTCAGGTTTAGAGCCACGA
rGAPDH TGGGAAGCTGGTCATCAAC GCATCACCCCATTTGATGTT
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ELISA Kit (Shanghai, China), Human/Mouse/Rat Angiotensin
II Enzyme Immunoassay Kit (RayBiotech, Inc.), Nitrate/Nitrite
Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI,
USA), cGMP Assay Kit (Cayman Chemical, Ann Arbor, MI,
USA), Renin Inhibitor Screening Assay Kit (Cayman Chemical,
Ann Arbor, MI, USA) were purchased.
Plant Material
Stem bark of U. wallichiana was collected and authenticated
by Arya et al. (2013) of CSIR–Central Drug Research Institute
(CDRI), Lucknow, India and extraction procedure was reported
(Sharan et al., 2010; Arya et al., 2013; Maurya et al., 2014).
EE and BF from stem bark of U. wallichiana were obtained
from Medicinal and Process Chemistry division of CSIR–
CDRI, Lucknow, India. The fingerprinting of EE and BF of
U. wallichiana was done by us using LC-MS/MS – Mass
spectrometer QTrap 5500-AB (Applied Biosystems/MDS Sciex,
Canada), using an electrospray ionization source in negative ion
mode (ESI) and published (Syed et al., 2016).
Animals
The experiments were carried out with male normotensive wistar
rats (180–220 g) procured from the Laboratory Animal Division
of CSIR–CDRI, Lucknow, India. Experiments were performed
according to protocols approved by Institutional Animal Ethics
Committee [(IAEC) no. IAEC/2012/92N] of CSIR–CDRI and
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), India. Rats were maintained
under standard housing conditions (room temperature 25± 2◦C
and humidity 60± 5%) with a 12 h light and dark cycle. Food and
water were available ad libitum.
Study Protocols
Male wistar rats were injected subcutaneously (s.c.) with ISO
5 mg/kg/day for 10 days (Yeh et al., 2010) with or without
500 mg/kg/day of EE and 50 mg/kg/day of BF of U. wallichiana.
The rats were randomly divided into four groups and each group
contains six animals each.
(i) Control group: olive oil (vehicle) was given s.c. for 10 days.
(ii) ISO group: Isoprenaline, 5 mg/kg/day was administered
subcutaneously for 10 days, to induce cardiac hypertrophy.
(iii) ISO+ EE group: EE was administered orally for 14 days at a
dose of 500 mg/kg/day of U. wallichiana after development
of cardiac hypertrophy.
(iv) ISO + BF group: Oral administration of BF for 14 days at
a dose of 50 mg/kg/day of U. wallichiana after development
of cardiac hypertrophy.
Blood Pressure Measurement
NIBP Measurement
To measure changes in arterial blood pressure in conscious rat,
NIBP technique was used (Columbus instrument, Model NIBP-
8). Conscious rats were acclimatized in the restrainer for 15 min
three times a day for a period of 1-week before the starting of the
testing schedule. The trained animals were placed in a restrainer
and tails of rats were exposed to hot air blower. The rats were
allowed to acclimatize inside the cage for 15 min before starting
the actual blood pressure measurement. Occlusion and sensor
cuffs were placed around the base of the tail and the cuffs were
inflated and deflated several times to measure tail arterial blood
pressure. A minimum of 8–10 cycles of inflation and deflation
were made and the measurement of tail arterial blood pressure
was recorded and the data was averaged. The data were recorded
and analyzed with software.
IBP Measurement
Arterial blood pressure was measured by invasive method in
the urethane (1.2 g/kg) anesthetized rats. The tracheotomy was
performed. The catheter was inserted into the carotid artery to
monitor the alteration in the arterial blood pressure. The other
end of the catheter was connected to the computerized Data
Acquisition System (DAS), AD-Instruments with compatible
software.
Determination of Heart Weight to Body
Weight Ratio, Heart Weight to Tail Length
Ratio, and Heart Weight to Tibia Length
Ratio
After the measurement of IBP the rats were sacrificed and heart
weight, tail length, and tibia length were measured. The heart
weight index was calculated by dividing the heart weight by the
body weight (Yeh et al., 2010), the heart tail index was calculated
by dividing the heart weight by tail length (Chowdhury et al.,
2013), and the heart tibia index was calculated by dividing the
heart weight by tibia length (Oh et al., 2015).
Renin Inhibition Assay
The renin inhibition assay was performed by Renin Inhibitor
Screening Assay Kit (catalog number: 10006270; Chemical, Ann
Arbor, MI, USA) according to the manufacturer’s instructions.
The renin inhibition was expressed as percentage inhibition or
percent initial activity as a function of the inhibitor concentration
to determine the IC50 value.
Estimation of Plasma Renin Level in
Plasma
The plasma renin assay was measured by rat Renin (Renin)
ELISA kit (catalog number: E02R0022; BlueGene Biotech,
Shanghai, China) according to the manufacturer’s instructions.
To determine renin level, the blood was collected from the retro–
orbital plexus of rat in EDTA containing tubes. Plasma was
harvested by using centrifugation at 1000 × g for 15 min at 4◦C.
Plasma (100 µL) was used for estimation of renin concentration.
Angiotensin Converting Enzyme (ACE)
Assay
Angiotensin converting enzyme activity was determined by a
spectrophotometric mono-reagent assay. The reaction mixture
containing serum (10 µL) and the substrate solution (200 µL)
were kept at 37◦C in Elisa plate reader (BIOTEK, USA) and
reaction was monitored at 340 nm for 30 min. Serum ACE activity
was expressed as unit/L (Hanif et al., 2009).
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Determination of Angiotensin II (Ang II)
Level in Plasma
The plasma AG II level was estimated by Human/mouse/Rat
Ang II Enzyme Immunoassay Kit (catalog#: EIA-ANGII, EIAM-
ANGII, EIAR-ANGII; RayBiotech, Inc.) according to the
manufacturer’s instructions.
Estimation of Nitrate/Nitrite (NO) Level in
Plasma
The plasma NO was estimated by Nitrate/Nitrite Colorimetric
Assay Kit (catalog number: 780001; Cayman Chemical, Ann
Arbor, MI, USA) according to the manufacturer’s instructions.
To determine nitrate/nitrite level in plasma, 40 µL of plasma was
taken and diluted with 40 µL of Assay Buffer to adjust the volume
to 80 µL of sample and used for NO determination.
Estimation of cGMP Level in Plasma
The cGMP concentrations were estimated using an enzyme
immunoassay (EIA) kit (catalog number: 581021; Cayman
Chemical, Ann Arbor, MI, USA), as per the manufacturer’s
instructions. To determine the cGMP levels in plasma, 2 mL of
ice-cold ethanol was added to 500 µL of plasma, and the solution
was centrifuged at 1500 × g for 10 min. The supernatant was
evaporated by vacuum centrifugation (Turbo Vap LV, Caliper,
USA) and used for the cGMP estimation.
Determination of Reactive Oxygen
Species (ROS)
Reactive oxygen species was estimated in heart tissue. Heart tissue
was homogenized in ice-cold 40 mMtris buffer (pH 7.4) and
samples were centrifuged at 100,000 × g at 4◦C in an Eppendorf
centrifuge (5819 R Germany) for 15 min. The resulting heart
homogenate was incubated with DCFDA (5 µM) for 30 min at
37◦C. Formation of fluorescent product DCF was monitored by
fluorometer at an excitation wavelength of 488 nm and emission
wavelength of 530 nm.
Histopathological Examination
After measurement of hemodynamic parameters of rats, their
hearts were quickly and filled with 4% paraformaldehyde
solution, and kept in it for 24 h. The heart samples were
embedded in paraffin blocks. Samples were sliced of 5 µm
thickness and stained with hematoxylin and eosin (H&E) for
assessing myocardial fibrosis. Myocardial fibrosis and relative cell
surface area were evaluated in each of the heart tissue sections
using a morphometric procedure using ImageJ software.
RNA Extraction and Relative Gene
Expression Analysis by Real-Time PCR
Total RNA Extraction
Total RNA was extracted from 0.1 to 0.2 g of rat heart tissues
by using TRIzol reagent as per manufacturer’s protocol. The
quality and quantity of the isolated RNA were assessed using
the 260/280 nm absorbance ratio (1.8–2.0 indicates a highly pure
sample) using NanoDrop 2000c spectrophotometer (USA). Total
RNA was stored at−80◦C until used.
Synthesis of cDNA and RT qPCR Quantification
RNA was transcribed into cDNA in a 20 µL reaction using a High
Capacity RNA to cDNA Reverse Transcriptase kit, analyzed, and
amplified. 2x master mixes were prepared using 2 µl 10x Reverse
Transcription buffers, 0.8 µL 25x dinucleotide triphosphate
(dNTP) mix (100 mM), 2 µL 10x Reverse Transcription random
primers, and 1 µL MultiScribe Reverse Transcriptase. For a
20 µL reaction mixture under the following conditions: 5.8 µL
master mix; 2 µL of 2 µg RNA sample; 12.2 µL nuclease free
water. Following was the program for reverse transcriptase PCR
using SureCycler 8800 (Agilent Technologies, USA): 25◦C for
10 min; 37◦C for 120 min; 85◦C for 5 min; hold at 4◦C. The
product obtained was diluted 4× for real-time PCR. Samples
were seeded in triplicate in 96-well reaction plates (LightCycler
480). RT qPCR was performed on Light Cycler 480 II (Roche
Diagnostics) with SYBR Green fluorescent label. Samples (10 µL
final volume) contained the following: 2x SYBR Premix Ex
Taq 1 µL of each primer; 3 µL of cDNA sample, and 5 µL
of nuclease free water. Cycle threshold (Ct) values were used
to calculate the amount of amplified PCR product relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control
(reference gene).
Statistical Analysis
Statistical analysis was performed with Prism software version
5.01 (Graph Pad Software, San Diego, CA, USA) and Curve
Expert Professional version 2.0.3. Results are expressed as
mean ± SEM. Statistical significance was evaluated by one-
way analysis of variance (ANOVA) followed by Newman–Keuls
Multiple comparison test and t-test. A value of p < 0.05 was
considered to be statistically significant.
RESULTS
U. wallichiana Attenuated Heart Weight
to Body Weight Ratio, Heart Weight to
Tail Length Ratio, and Heart Weight to
Tibia Length Ratio
Heart to body weight, heart weight to tail length, and heart
weight to tibia length ratio were significantly increased in the
ISO groupas compared to control group. The treatment of
extract and fraction of U. wallichiana significantly decreased
heart to body weight, heart weight to tail length, and heart
weight to tibia length ratio in ISO+EE and ISO+BF group
compared to disease control (Figures 1A–C), respectively. The
images of whole heart have been provided in the Supplementary
Figure 3.
Hemodynamics
Blood pressure and HR were significantly increased in ISO
induced cardiac hypertrophy as compared to normotensive
Wistar group (Figures 2A–C). The treatment of extract and
fraction of U. wallichiana significantly decreased the SBP in
ISO+EE and ISO+BF compared to diseased control (Figure 2A)
and it also decreased the HR in ISO+EE and ISO+BF compared
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FIGURE 1 | Effect of Ulmus wallichiana on (A) Heart weight to body weight ratio, (B) Heart weight to tail length ratio, and (C) Heart to tibia length ratio in ISO
induced cardiac hypertrophy in wistar rats. Data were analyzed by using one-way ANOVA followed by Newman–Keuls Multiple comparison test. Data are shown as
Mean ± SEM; α, control vs. ISO; β, ISO vs. EE; γ, ISO vs. BF; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
to diseased control (Figure 2D), respectively. (In support IBP
data is given in Supplementary Figures 2A–D.)
Renin Inhibition
Renin inhibition assay in vitro was conducted to assess the renin
inhibitory properties of EE and BF of U. wallichiana. The IC50
value for EE was found to be 12.5 µg/mL and that of BF was
5.5 µg/mL (Figures 3E,F)
U. wallichiana Reduced Plasma Renin
Concentration
The plasma renin concentration was increased significantly in
ISO group. Administration of EE and BF of U. wallichiana
significantly decreased plasma renin concentration in ISO+EE
and ISO+BF group compared to diseased control (Figure 3A)
group, respectively.
U. wallichiana Decreased ACE Activity
The plasma ACE activity was increased significantly in ISO
group. Further administration of EE and BF of U. wallichiana
significantly decreased ACE activity in ISO+EE and ISO+BF
group compared to diseased control (Figure 3B) group,
respectively.
U. wallichiana Attenuated AG II
Concentration in Plasma
The plasma Ang II level was increased significantly in ISO
group. Further administration of EE and BF of U. wallichiana
significantly decreased ACE activity in ISO+EE and ISO+BF
compared to diseased control (Figure 3D) group, respectively.
U. wallichiana Increased Plasma
Nitrite/Nitrate (NO) Concentration
The concentration of NO was decreased significantly in ISO
group. Further administration of EE and BF of U. wallichiana
significantly increased NO in ISO+EE and ISO+BF group
compared to diseased control (Figure 3C) group, respectively.
U. wallichiana Increased cGMP
Concentration
The concentration of cGMP was decreased significantly in ISO
group. Further administration of EE and BF of U. wallichiana
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FIGURE 2 | Effect of U. wallichiana on BP (A) SBP, (B) DBP, (C) MAP, and (D) HR by NIBP measurement technique in ISO induced cardiac hypertrophy in wistar
rats. Data were analyzed by using one-way ANOVA followed by Newman–Keuls Multiple comparison test. Data are shown as Mean ± SEM; α, control vs. ISO; β,
ISO vs. EE; γ, ISO vs. BF; ∗∗P < 0.01, ∗∗∗P < 0.001.
significantly increased cGMP concentration in ISO+EE and
ISO+BF group compared to diseased control (Figure 4A) group,
respectively.
U. wallichiana Attenuated ROS Level
The ROS activity was increased significantly in ISO group.
Further administration of EE and BF of U. wallichiana
significantly increased ROS activity in ISO+EE and ISO+BF
group compared to diseased control (Figure 4B) group,
respectively.
U. wallichiana Reduced Expression of
Cardiac Hypertrophic Markers
To investigate whether EE and BF of U. wallichiana confers
cardio-protection in ISO treated group. We have determined
the cardiac gene expression of ANP, BNP, TNF-α, IL-6, TGFβ1,
MMP9, β1-AR, ACE2, Mas relative to ISO treated group. ISO
caused significant up regulation of ANP, BNP, TNF-α, IL-6,
TGFβ1, MMP9, β1-AR and down regulation of NOS3, ACE2,
Mas as compared to control group. On treatment with the EE and
BF of U. wallichiana the ANP, BNP, TNF-α, IL-6, TGFβ1, MMP9,
β1-AR was significantly reduced in ISO+EE and ISO+BF group
and significantly increased in NOS3, ACE2, Mas expression as
compared to diseased control group, respectively, (Figure 4E).
U. wallichiana Decreased Cardiac
Fibrosis and Relative Cell Surface Area
The regularly arranged myocardial fibers with clear striations
were observed in the control group (Figure 5A). The
photomicrograph of heart from normal group shows no
pathological alteration. The histological sections of the heart
obtained from ISO group showed enlargement of cardiomyocyte
showing increased cell radius with eccentric positioning of
nucleus indicating hypertrophy. Fibrocytic proliferation was also
invariably observed along with cellular degenerative changes
characterized by scanty cytoplasm and vacuolation. Focal
infiltration of inflammatory cells is observed in few animals.
There was significant increase in myocardial fibrosis in ISO
group (Figure 5B). There was also significant increase in relative
cell surface area in ISO group. On administration of EE and
BF of U. wallichiana significantly decreased myocardial fibrosis
in ISO+EE and ISO+BF group compared to diseased control
(Figures 4C and 5C,D); decreased relative cell surface area in
ISO+EE and ISO+BF group as compared to diseased control
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FIGURE 3 | Effect of U. wallichiana on (A) renin concentration, (B) angiotensin converting enzyme (ACE) activity, (C) NO concentration, (D) Ang II concentration,
(E) inhibition of human recombinant renin by EE and (F) inhibition of human recombinant renin by BF in ISO induced cardiac hypertrophy in wistar rats. Data were
analyzed by using one-way ANOVA followed by Newman–Keuls Multiple comparison test. Data are shown as Mean ± SEM; α, control vs. ISO; β, ISO vs. EE; γ, ISO
vs. BF; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
(Figures 4D and 5C,D) group, respectively. A representative
photo has also been given in the Supplementary Figure 4.
DISCUSSION
In the present study, the U. wallichiana attenuated cardiac
hypertrophic response induced by ISO, a non-selective
β-adrenoceptor agonist. The EE and BF of U. wallichiana
attenuated cardiac hypertrophy by decreasing SBP and HR and
inhibiting plasma renin, ACE, Ang II and augmented plasma
NO and cGMP concentration (Supplementary Table 2). The
EE and BF of U. wallichiana have antihypertensive activity
(Syed et al., 2016). ISO in chronic dose not only produced
cardiac hypertrophy but also altered the gross structure of the
heart. There was an increase in weight of the heart, but no
significant effect on weight of the body. The effect of EE and BF
of U. wallichiana was studied as anti-hypertrophic. The dose of
EE (500 mg/kg) and BF (50 mg/kg) of U. wallichiana contains
quercetin analog flavonoids K058: 9.79 and 1.34 mg, K012: 4.33
and 0.24 mg, K068: 0.625 and 0.15 mg, and K100: 2.49 and
0.41 mg, respectively.
The EE and BF of U. wallichiana decreased the heart
rate, renin release, and Ang II level there by decreasing the
cardiac output. ISO, a directly acting catecholamine, binds
with the β-adrenergic receptor in heart and causes significant
increase in heart rate (Arnold and McDevitt, 1983), increased
plasma renin and Ang II level (Leenen et al., 2001). ISO,
a sympathetic β-adrenergic receptor agonist, stimulates renin
release via adenylate cyclase-cyclic AMP system (Suzuki and
Hashiba, 1986). The stimulatory effect of ISO on renin release was
inhibited by the EE and BF of U. wallichiana due to the presence
of quercetin analog flavonoids. Renin overproduction increases
the level of Angiotensin I in the blood, leading to high BP. The
IC50 value for EE was found to be 12.5 µg/mL and that of BF was
5.5 µg/mL, showing renin inhibition in the present study.
Cardiac mast cell secretes renin initiating the formation
of angiotensinogen. Cardiac mast cells releases renin on
degranulation by ROS. Renin initiates the activation of a local
renin-angiotensin system which culminates in the formation of
Ang II (Reid et al., 2011). The quercetin analog flavonoids acts as
antioxidant and inhibits release of pro-inflammatory cytokines,
IL-6 from mast cell. Therefore the EE and BF of U. wallichiana
attenuates the ROS production, due to its antioxidant activity,
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FIGURE 4 | Effect of U. wallichiana on (A) cGMP concentration, (B) fluorescence intensity, (C) myocardial fibrosis, (D) relative cell surface area, and (E) relative
mRNA expression level of ANP, BNP, IL-6, NOS3, TNF-α, TGFβ1, MMP9, β1 adrenergic receptor (β1 AR), ACE2 and Mas in ISO induced cardiac hypertrophy in
wistar rats. Data were analyzed by using one-way ANOVA followed by Newman–Keuls Multiple comparison test. Data are shown as Mean ± SEM, α, control vs.
ISO; β, ISO vs. EE; γ, ISO vs. BF; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
inhibiting the TNF-α and IL-6 and it has renin inhibition
property (Figures 3E,F). Thus EE and BF may be responsible to
inhibit the release of renin from the cardiac mast cells.
Angiotensin converting enzyme, an enzyme that regulates
RAAS pathway, contains zinc and a zinc ion (Ojeda et al., 2010).
The flavonoids quercetin analog forms chelate complex with zinc
and inhibit the ACE enzyme (Actis-Goretta et al., 2006; Guerrero
et al., 2012). The ACE2 and Mas receptors are involved in the
cardiac hypertrophy as their reduced expression is found in
hypertrophied heart (Zhang et al., 2014). ACE2, by degradation
of Ang II, forms Ang (1–7) which opposes actions of Ang II
by binding to the Mas receptor leading to vasodilation, anti-
hypertrophic and anti-fibrotic effect (Dias-Peixoto et al., 2012).
The EE and BF of U. wallichiana increased the ACE2 and Mas
receptor gene expression as compared to the ISO group.
In RAS pathway, increased renin and ACE enzyme causes
increased level of Ang II. Angiotensin II activates NAD(P)H
oxidase leading to oxidative stress (Veresh et al., 2008) causing
decrease in bioavailability of NO resulting in endothelial
dysfunction and vasoconstriction of arterioles leading to
hypertension. Emerging evidence suggests that the nitricoxide
(NO)/guanosine 3′5′-cyclic monophosphate (cGMP) pathway
plays an important role in the modulation of cardiac hypertrophy
(Ozaki et al., 2002). Therefore the EE and BF of U. wallichiana
increased the bioavailability of NO/cGMP leading to vasodilation
and act as anti-hypertrophic (Tirziu and Simons, 2008). As
NO has anti-hypertrophic effect which is mediated by cGMP
which involves cGMP-dependent protein kinase I activation.
Plasma NO level was decreased by ISO, an indirect indicator of
endogenous NO production.
NO/sGC/cGMP/cGMP dependent protein kinase G acts as
cardioprotective. U. wallichiana causes increase in the NO
level, probably via signal transduction pathway which results in
cGMP generation. Cardiovascular diseases are associated with
the impairment of Nitric oxide/soluble guanylate cyclase/cGMP
signaling (Korkmaz et al., 2009). NO/cGMP/ANP act as anti-
hypertrophic. ANP and BNP are present in cardiac tissues
(London, 2006), and act as cardiac hypertrophic markers
(Althurwi et al., 2013).
The cardiac mast cell induces MMP activation due to oxidative
stress as well as TNF-α which causes degradation of collagen
causing cardiac fibrosis in cardiac hypertrophy (Lee et al., 2010;
Parthasarathy et al., 2014). ROS also have potent effects on the
extracellular matrix, stimulating cardiac fibroblast proliferation
Frontiers in Pharmacology | www.frontiersin.org 8 December 2016 | Volume 7 | Article 510
fphar-07-00510 December 19, 2016 Time: 14:56 # 9
Syed et al. Ulmus wallichiana in Cardiac Hypertrophy
FIGURE 5 | Representative photomicrographs of heart dyed with haematoxylin and eosin (H&E) stain (10× and 40× magnification). (A) Control, (B) ISO,
(C) ISO+EE, (D) ISO+BF groups, respectively.
FIGURE 6 | Schematic diagram showing the mechanism of action of EE and BF of U. wallichiana in ISO induced cardiac hypertrophy. ACE, angiotensin
converting enzyme; cGMP, cyclic guanosine monophosphate; NOS, nitric oxide synthase.
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and activating MMPs. EE and BF of U. wallichiana attenuates
the increased expression of TGFβ1, MMP9, and ROS activity.
TNF-α, IL-6 are cytokines which mediates various physiological
and pathological functions like inflammation, cellular survival,
growth, differentiation, and apoptosis. TNF-α in the myocardium
produce inflammation and apoptosis via TNFR1 receptor (Sack
et al., 2000) where as IL-6 also produce cardiac hypertrophy,
fibrosis, and inflammation (Diaz et al., 2009; Meléndez et al.,
2010). The flavonoids and quercetin analogs present in EE and
BF of U. wallichiana act as antioxidant (LaManna et al., 2011;
Brunetti et al., 2013) thus decreasing ROS activity.
CONCLUSION
We suggest that the quercetin analog flavonoids present
in the EE and BF of U. wallichiana attenuated cardiac
hypertrophy (Figure 6) showing cardioprotective effect. The BF
showed pharmacological response and potent at a lower dose
(50 mg/kg/day) as compared to EE (500 mg/kg/day) as BF
contains higher concentration of flavonoids than EE (Sharan
et al., 2010).
Thus, the EE and BF of U. wallichiana showed
cardioprotective effect against ISO induced cardiac hypertrophy.
Based on these findings the marker compounds present in
U. wallichiana can be isolated to study the mechanism of action
and it may be a novel therapeutic agent for treatment of cardiac
hypertrophy.
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